Harvard Bioscience (NASDAQ:HBIO - Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of $0.05 per share for the quarter. Harvard Bioscience has set its FY 2024 guidance at EPS.Parties that are interested in registering for the company's conference call can do so using this link.
Harvard Bioscience (NASDAQ:HBIO - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The medical instruments supplier reported ($0.03) earnings per share for the quarter, missing the consensus estimate of $0.03 by ($0.06). The firm had revenue of $23.10 million for the quarter, compared to analyst estimates of $29.91 million. Harvard Bioscience had a negative return on equity of 2.70% and a negative net margin of 10.56%.
Harvard Bioscience Price Performance
Shares of HBIO traded down $0.10 on Thursday, hitting $2.35. The company's stock had a trading volume of 62,683 shares, compared to its average volume of 113,688. The company has a 50 day moving average price of $2.65 and a 200 day moving average price of $3.02. Harvard Bioscience has a fifty-two week low of $2.30 and a fifty-two week high of $5.56. The company has a market capitalization of $102.06 million, a PE ratio of -11.90 and a beta of 1.29. The company has a debt-to-equity ratio of 0.48, a current ratio of 2.05 and a quick ratio of 0.94.
About Harvard Bioscience
(
Get Free Report)
Harvard Bioscience, Inc develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings.
See Also
Before you consider Harvard Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Harvard Bioscience wasn't on the list.
While Harvard Bioscience currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
